Bioanalytics – Biomolecular
The ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RIS) IMI (Innovative Medecines Initiative) activities started in February 2012 and ended April 2018.
The objectives of ABIRISK were the following:
- Provide a complementary expertise for anti-drug antibodies (ADA) assays: standardization and characterization of ADA
- Develop Novel integrated approaches to characterize AD lymphocyte responses
- Development and validation of innovative prediction tools (in silico, in vitro, in vivo)
- Collection and integration of immunogenicity-related data and clinical relevance of ADA in one data bank
To achieve these tasks, ABIRISK worked in 4 therapeutic areas: multiple sclerosis (MS), inflammatory bowel diseases (IBD), rheumatoid arthritis (RA) and hemophilia A. In MS, RA and IBD ABIRISK recruted more than 500 patients in prospective cohorts.
In this symposia, results from ABIRISK concerning the following items will be presented: Understanding mechanism of immunogenicity including the identification of early signature of ADA response, Characteristics of ADA and production of ADA assay standards, Clinical observations and Genetic associations.
The attendees will have the opportunity to discover original and exciting results in the field of biotherapeutics immunogenicity.